MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319534 | Name: Ravidasvir HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ravidasvir, also known as PPI-668 and ASC16, is a second-generation, orally active, potent and selective hepatitis C virus (HCV) non-structural protein 5A (NS5A) protein inhibitor.

Chemical Structure

Ravidasvir HCl
Ravidasvir HCl
CAS#1303533-81-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 319534

Name: Ravidasvir HCl

CAS#: 1303533-81-4 (HCl)

Chemical Formula: C42H52Cl2N8O6

Exact Mass: 0.0000

Molecular Weight: 835.83

Elemental Analysis: C, 60.35; H, 6.27; Cl, 8.48; N, 13.41; O, 11.48

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1242087-93-9 (free base) 1303533-81-4 (HCl)
Synonym
PPI-668; PPI 668; PPI668; ASC16; ASC-16; ASC 16; BI238630; C5; Ravidasvir dihydrochloride
IUPAC/Chemical Name
methyl N-[(2S)-1-{(2S)-2-[5-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}naphthalen-2-yl)-1H-benzimidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate dihydrochloride
InChi Key
JYLMWUZJMRNMDA-SPRBZRACSA-N
InChi Code
InChI=1S/C42H50N8O6.2ClH/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6;;/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54);2*1H/t33-,34-,35-,36-;;/m0../s1
SMILES Code
O=C(OC)N[C@@H](C(C)C)C(N1[C@H](C2=NC3=CC(C4=CC=C5C=C(C6=CNC([C@H]7N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC7)=N6)C=CC5=C4)=CC=C3N2)CCC1)=O.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ravidasvir inhibits HCV replication in Huh7 replicon cells containing NS5A from the HCV genotypes 1a, -1b, and 3a with EC50 values of 0.12, 0.01, and 1.14 nM, respectively.
In vitro activity:
Molecular docking results showed that ravidasvir was found to be a potent inhibitor of 3CLpro. This study suggests that ravidasvir might be a potential lead molecule against SARS-CoV-2. Reference: J Biomol Struct Dyn. 2022 Oct;40(16):7303-7310. https://pubmed.ncbi.nlm.nih.gov/33682639/
In vivo activity:
Ravidasvir plus sofosbuvir was effective and well tolerated in a phase 2/3 clinical trial of patients with chronic hepatitis C virus infection. Ravidasvir plus sofosbuvir has the potential to provide an additional affordable, simple, and efficacious public health tool for large-scale implementation to eliminate hepatitis C as a cause of morbidity and mortality. Reference: Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. https://pubmed.ncbi.nlm.nih.gov/33865507/
Solvent mg/mL mM
Solubility
DMF 5.0 5.98
DMSO 5.0 5.98
Ethanol 1.0 1.20
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 835.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Bera K. Binding and inhibitory effect of ravidasvir on 3CLpro of SARS-CoV-2: a molecular docking, molecular dynamics and MM/PBSA approach. J Biomol Struct Dyn. 2022 Oct;40(16):7303-7310. doi: 10.1080/07391102.2021.1896388. Epub 2021 Mar 8. PMID: 33682639. 2. Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16. Erratum in: Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. PMID: 33865507; PMCID: PMC9767645. 3. Xiao L, Wu X, Zhang F, Wang J, Xu X, Li L. Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection. J Med Virol. 2020 Jun 11. doi: 10.1002/jmv.26161. Epub ahead of print. PMID: 32525562.
In vitro protocol:
1. Bera K. Binding and inhibitory effect of ravidasvir on 3CLpro of SARS-CoV-2: a molecular docking, molecular dynamics and MM/PBSA approach. J Biomol Struct Dyn. 2022 Oct;40(16):7303-7310. doi: 10.1080/07391102.2021.1896388. Epub 2021 Mar 8. PMID: 33682639.
In vivo protocol:
1. Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16. Erratum in: Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. PMID: 33865507; PMCID: PMC9767645. 2. Xiao L, Wu X, Zhang F, Wang J, Xu X, Li L. Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection. J Med Virol. 2020 Jun 11. doi: 10.1002/jmv.26161. Epub ahead of print. PMID: 32525562.

View History

A2315A

A2315A